Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Neutropenia Prevention in Cervical Cancer
NCT04542356Phase 2Completed
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Aug 2018
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Incidence of Grade 3-4 neutropenia at 2 months and Duration of Grade 3-4 neutropenia at 2 months. Started Aug 2018; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04542356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542356.